Volume 17 May 8, 2019
RxReins is a dedicated Managing General Underwriter (MGU) specializing in prescription stop loss insurance for group benefit plans. We work closely with Brokers, TPAs and PBMs to provide the best available products from multiple A-rated carriers in all fifty states . RxReins is a member of the ELMC Risk Solutions family of companies.
Is 'High Dollar' About to Become the New Normal in Specialty Pharmacy?

"We are rapidly approaching new heights in terms of what the term “high dollar” could mean in the current and future health care space. As some specialty therapies have cleared the 6-figure mark, manufacturers, payers, specialty pharmacies, and health systems are being forced to reinvent the wheel.
The next wave of pharmaceutical products being developed are focused on targeted gene therapies for rare disease states that affect small populations. As the therapies within this pipeline come to market, they will invariably alter the current infrastructure and could be replaced by a system that supports the dispensing, billing, and distribution of these new drugs."  

Whistleblowers Say Drugmaker Bribed Doctors to Increase Sales

" The whistleblowers accused Questcor Pharmaceuticals, now Mallinckrodt, of using a “multi-tiered strategy” to boost sales of the drug H.P. Acthar Gel, used to treat a rare infant seizure disorder. The drug’s price has spiked nearly 97,000 percent in the past two decades, from $40 per vial in 2000 to almost $39,000, according to CNN. Much of the increase occurred before Mallinckrodt acquired the company in 2014, though the price hikes have continued in the last five years."

First Treatment for All Genotypes of Hepatitis C in Children Receives FDA Approval

" The FDA today approved AbbVie’s glecaprevir and pibrentasvir (Mavyret) tablet to treat all 6 genotypes of hepatitis C virus (HCV) in children ages 12 to 17 years. ccording to the CDC, an estimated 2.7 to 3.9 million people in the U.S. have chronic HCV, and children born to HCV-positive mothers are at risk for HCV infection. It is estimated that there are 23,000 to 46,000 children in the U.S. with HCV infection."

RxReins Frequently Asked Questions
What Corridor Options Do We Offer?
Do We Cover Specialty Drugs?

Register for our webinar to learn more about RxReins.
RxReins, LLC | 888.797.3467 | Stoploss@Rxreins.com | www.rxreins.com